Spherix Incorporated (NASDAQ: SPEX), an intellectual property development company committed to the fostering of technology, today announced the formation of a Technology Advisory Board in the area of biopharmaceutical opportunities.

The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena, as well as to advise the Company in its work with Hoth Therapeutics. As previously reported, the Company recently acquired a controlling interest in Hoth Therapeutics, a company involved in the development of a novel topical treatment for patients suffering from atopic dermatitis, such as eczema. Individuals serving on the advisory board will provide the Company advice, support and technical assistance in reviewing diversification opportunities. The Company will announce the members and their respective credentials as they join.

Anthony Hayes, the Chief Executive Officer of Spherix stated, "As we continue to diversify and build the intrinsic value of Spherix, we believe the advisory board will provide valuable insights to the Company and its prospects. We are excited about our future growth potential."

About Spherix Incorporated

Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by participation in the development of new technology. Spherix draws on portfolios of pioneering technology to support product innovation.